Genomic Analysis of Plasma Cell-Free DNA for Lung Cancer Management: An Imperfect Biomarker, But We Love It Anyway
April 10, 2018 | Online

Overview

Plasma cell-free DNA is a compelling but complex biospecimen which we now use routinely in the care of lung cancer patients. This talk will review strategies for effectively interpreting results from plasma genotyping, well as methods for incorporating these assays into lung cancer care and lung cancer research.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to Dr. Oxnard and Dr. Govindan via internet chat.

What you should expect to learn

After attending this webinar, participants will be able to:

  • Assess the current role of genomic analysis of plasma cell-free DNA in the management of lung cancer.
  • Discuss strategies to incorporate these assays into standard clinical management of lung cancer.
  • Identify ongoing clinical trials likely to further elucidate the role and affect the use of genomic analysis in the near future.

Geoffrey R. Oxnard, MD
Damon Runyon-Gordon Family Clinical Investigator
Associate Professor of Medicine
Dana Farber Cancer Institute
Harvard Medical School

 Ramaswamy Govindan, MD - Program Chair

Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Contact